Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives $187.71 Consensus Target Price from Analysts

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) have received a consensus recommendation of “Moderate Buy” from the fourteen brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $187.71.

JAZZ has been the topic of several recent research reports. Piper Sandler reiterated an “overweight” rating and set a $176.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. JPMorgan Chase & Co. increased their price objective on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Barclays reiterated an “overweight” rating and set a $200.00 price objective (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $210.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 5th.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $138.76 on Wednesday. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The firm has a market capitalization of $8.43 billion, a P/E ratio of 19.54, a P/E/G ratio of 1.04 and a beta of 0.44. The stock’s 50-day simple moving average is $131.41 and its two-hundred day simple moving average is $121.79. Jazz Pharmaceuticals has a twelve month low of $99.06 and a twelve month high of $148.06.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 4,813 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $144.42, for a total value of $695,093.46. Following the completion of the sale, the chief accounting officer now owns 8,237 shares in the company, valued at approximately $1,189,587.54. This trade represents a 36.88 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CMO Robert Iannone sold 7,080 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $138.60, for a total value of $981,288.00. Following the completion of the sale, the chief marketing officer now owns 82,024 shares of the company’s stock, valued at approximately $11,368,526.40. This trade represents a 7.95 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 28,736 shares of company stock worth $4,022,825. 4.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of JAZZ. IFP Advisors Inc purchased a new stake in Jazz Pharmaceuticals in the 4th quarter worth approximately $25,000. Quadrant Capital Group LLC lifted its stake in shares of Jazz Pharmaceuticals by 97.1% in the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 101 shares during the period. Elequin Capital LP lifted its stake in shares of Jazz Pharmaceuticals by 677.8% in the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 183 shares during the period. CoreFirst Bank & Trust purchased a new position in shares of Jazz Pharmaceuticals in the 4th quarter valued at approximately $28,000. Finally, Allianz SE purchased a new position in shares of Jazz Pharmaceuticals in the 4th quarter valued at approximately $29,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.